查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1621721

實體腫瘤檢測市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Solid Tumor Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 105 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球實體瘤檢測市場估值為205 億美元，預計2024 年至2032 年複合年成長率為7.6%。的提高。癌症盛行率的上升極大地推動了對有效診斷能力的需求。隨著醫療保健提供者遇到越來越多的患有各種實體瘤的患者，他們有動力增強他們的測試方法，以確保有效治療和管理疾病。市場可分為基因檢測和常規檢測。

2023年，基因檢測成為主導領域，佔136億美元。此類測試提供了對腫瘤分子和遺傳特徵的全面了解，有助於制定個人化治療策略。透過將治療與特定的基因突變結合起來，基因檢測可以改善患者的治療結果。在考慮應用時，實體腫瘤檢測市場涵蓋多種類型，包括乳癌、肺癌、攝護腺癌、大腸直腸癌和黑色素瘤等。

專注於乳癌的細分市場佔據了最大的市場佔有率，反映出這種疾病在全球範圍內的高發病率，尤其是在女性中。這種盛行率強調了乳癌護理中對早期診斷和有效治療方案的巨大需求。在北美，實體瘤檢測市場2023年收入為77億美元，預計在預測期內複合年成長率為7.3%。這種成長的一個關鍵驅動力是對精準腫瘤學的日益關注，它根據個別腫瘤基因譜進行個人化治療。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 205 億美元
預測值 394 億美元
複合年成長率 7.6%

此外，次世代定序 (NGS) 等基因組技術的進步徹底改變了實體腫瘤檢測，可以對癌症突變和分子生物標記進行深入分析。隨著市場的不斷發展，對早期檢測和個人化治療方法的重視可能會塑造實體腫瘤檢測的未來，滿足對更有效的癌症管理解決方案不斷成長的需求。創新技術的整合將提高診斷準確性，並有助於改善各種癌症類型的患者預後。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 癌症發生率上升
      • 診斷技術的進步
      • 意識和需求不斷成長
      • 增加醫療支出和投資
    • 產業陷阱與挑戰
      • 資本要求高
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 報銷場景
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 基因檢測
    • 新一代定序（NGS）
    • 螢光原位雜合技術（FISH）
    • 聚合酶鍊式反應 (PCR)
    • 原位雜合技術（ISH）
  • 常規測試

第 6 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 大腸直腸癌
  • 黑色素瘤
  • 其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 癌症研究機構
  • 其他最終用途

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Abbott
  • Agilent Technologies, Inc.
  • Caris Life Sciences
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Guardant Health
  • Hologic, Inc.
  • Illumina, Inc.
  • MedGenome
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • QIAGEN
  • Quest Diagnostics Incorporated
  • SOPHiA GENETICS
  • Thermo Fisher Scientific, Inc.
簡介目錄
Product Code: 11699

The Global Solid Tumor Testing Market was valued at USD 20.5 billion in 2023 and is projected to grow at a CAGR of 7.6% from 2024 to 2032. This growth is driven by an increase in cancer cases and heightened awareness regarding the importance of timely and accurate diagnostic solutions. The rising prevalence of cancer significantly fuels the demand for effective diagnostic capabilities. As healthcare providers encounter more patients with various solid tumors, they are motivated to enhance their testing methodologies to ensure effective treatment and management of the disease. The market can be categorized into genetic testing and conventional testing.

In 2023, genetic testing emerged as the dominant segment, accounting for USD 13.6 billion. This type of testing offers comprehensive insights into the molecular and genetic profiles of tumors, which facilitates personalized treatment strategies. By aligning therapies with specific genetic mutations, genetic testing can lead to improved patient outcomes. When considering applications, the solid tumor testing market encompasses various types, including breast cancer, lung cancer, prostate cancer, colorectal cancer, and melanoma, among others.

The segment focused on breast cancer held the largest market share, reflecting the high rates of this disease globally, especially among women. This prevalence underscores the significant need for early diagnosis and effective treatment options in breast cancer care. In North America, the solid tumor testing market generated revenue of USD 7.7 billion in 2023 and is expected to grow at a CAGR of 7.3% during the forecast period. A key driver of this growth is the increasing focus on precision oncology, which personalizes treatment based on individual tumor genetic profiles.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$20.5 Billion
Forecast Value$39.4 Billion
CAGR7.6%

Furthermore, advancements in genomic technologies, such as next-generation sequencing (NGS), have revolutionized solid tumor testing, allowing for in-depth analysis of cancer mutations and molecular biomarkers. As the market continues to evolve, the emphasis on early detection and personalized treatment approaches is likely to shape the future of solid tumor testing, addressing the growing demand for more effective cancer management solutions. The integration of innovative technologies will enhance diagnostic accuracy and contribute to better patient outcomes across various cancer types.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising cancer incidences
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing awareness and demand
      • 3.2.1.4 Increased healthcare expenditures and investments
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High capital requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Reimbursement scenario
  • 3.7 Future market trends
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Genetic testing
    • 5.2.1 Next-generation sequencing (NGS)
    • 5.2.2 Fluorescence in situ hybridization (FISH)
    • 5.2.3 Polymerase chain reaction (PCR)
    • 5.2.4 In situ hybridization (ISH)
  • 5.3 Conventional testing

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Breast cancer
  • 6.3 Lung cancer
  • 6.4 Prostate cancer
  • 6.5 Colorectal cancer
  • 6.6 Melanoma
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic laboratories
  • 7.4 Cancer research institutes
  • 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 Agilent Technologies, Inc.
  • 9.3 Caris Life Sciences
  • 9.4 F. Hoffmann-La Roche Ltd
  • 9.5 Foundation Medicine, Inc.
  • 9.6 Guardant Health
  • 9.7 Hologic, Inc.
  • 9.8 Illumina, Inc.
  • 9.9 MedGenome
  • 9.10 Myriad Genetics, Inc.
  • 9.11 NeoGenomics Laboratories
  • 9.12 QIAGEN
  • 9.13 Quest Diagnostics Incorporated
  • 9.14 SOPHiA GENETICS
  • 9.15 Thermo Fisher Scientific, Inc.